Literature DB >> 19447437

The impact of obesity on overall and cancer specific survival in men with prostate cancer.

Benjamin J Davies1, Marc C Smaldone, Natalia Sadetsky, Marc Dall'era, Peter R Carroll.   

Abstract

PURPOSE: We examined the impact of obesity on disease specific and overall survival in patients with prostate cancer.
MATERIALS AND METHODS: We identified 7,274 men from the Cancer of the Prostate Strategic Urological Research Endeavor database with clinically localized prostate cancer, known body mass index and clinicopathological disease characteristics. Patients were classified by body mass index as normal (less than 25 kg/m(2)), overweight (25 to 29.9 kg/m(2)), obese (30 to 34.9 kg/m(2)) and severely obese (35 kg/m(2) or greater). Associations between body mass index and need for secondary treatment, disease specific survival and overall survival were analyzed using univariate and multivariate models.
RESULTS: Patients were classified by body mass index category as normal (28.8%), overweight (50%), obese (16.4%) and very obese (4.8%). Mean followup was 51.3 +/- 38.5 months. During followup there were 1,044 deaths with 220 (21.1%) from prostate cancer. Stratified by body mass index category the groups differed with regard to the need for secondary treatment (p = 0.05) and overall mortality (p <0.01) but there were no significant differences with regard to disease specific survival (p = 0.09). On multivariate analysis age 65 to 74 years (HR 2.4, p = 0.002), age older than 75 years (HR 3.2, p = 0.0001), high risk disease (HR 1.6, p <0.0001), conservative treatment (HR 1.2, p <0.0001) and presence of diabetes (HR 1.6, p <0.0001) were associated with decreased overall survival. Only conservative treatment (HR 1.4, p <0.0001), high risk disease (HR 8.4, p <0.0001) and intermediate risk disease (HR 2.5, p = 0.004) were associated with decreased disease specific survival.
CONCLUSIONS: In a prospective, community based cohort we were unable to establish a relationship between body mass index and prostate cancer disease specific survival or overall survival.

Entities:  

Mesh:

Year:  2009        PMID: 19447437     DOI: 10.1016/j.juro.2009.02.118

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

Review 1.  Obesity in cancer survival.

Authors:  Niyati Parekh; Urmila Chandran; Elisa V Bandera
Journal:  Annu Rev Nutr       Date:  2012-04-23       Impact factor: 11.848

Review 2.  Energetics in colorectal and prostate cancer.

Authors:  Jeffrey A Meyerhardt; Jing Ma; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 3.  Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis.

Authors:  S Zhong; X Yan; Y Wu; X Zhang; L Chen; J Tang; J Zhao
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-01-12       Impact factor: 5.554

4.  Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.

Authors:  Crystal S Langlais; Janet E Cowan; John Neuhaus; Stacey A Kenfield; Erin L Van Blarigan; Jeanette M Broering; Matthew R Cooperberg; Peter Carroll; June M Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-28       Impact factor: 4.254

5.  Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.

Authors:  P Pérez-Segura; J E Palacio; L Vázquez; S Monereo; R de Las Peñas; P Martínez de Icaya; C Grávalos; A Lecube; A Blasco; J M García-Almeida; I Barneto; A Goday
Journal:  Clin Transl Oncol       Date:  2017-01-10       Impact factor: 3.405

Review 6.  Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis.

Authors:  Yin Cao; Jing Ma
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-13

7.  Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.

Authors:  Alyssa N Troeschel; Terryl J Hartman; Eric J Jacobs; Victoria L Stevens; Ted Gansler; W Dana Flanders; Lauren E McCullough; Ying Wang
Journal:  J Clin Oncol       Date:  2020-04-06       Impact factor: 44.544

Review 8.  Late toxicity rates following definitive radiotherapy for prostate cancer.

Authors:  Nitin Ohri; Adam P Dicker; Timothy N Showalter
Journal:  Can J Urol       Date:  2012-08       Impact factor: 1.344

9.  Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model.

Authors:  Ashley Gray; William J Aronson; R James Barnard; Hemal Mehta; Junxiang Wan; Jonathan Said; Pinchas Cohen; Colette Galet
Journal:  J Endocrinol       Date:  2011-09-08       Impact factor: 4.286

10.  Oxidative stress and DNA methylation in prostate cancer.

Authors:  Krishna Vanaja Donkena; Charles Y F Young; Donald J Tindall
Journal:  Obstet Gynecol Int       Date:  2010-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.